Project Grant R61HL171790
Award Date
9/5/24
Completion Date
6/30/25
Dollars Obligated
$770K
Federal Agency
National Heart Lung and Blood Institute
Federal Grant Program
93.837
Assistance Type
Project Grant
Place of Performance
Salt Lake City, UT 84112, USA
Similar Awards
The National Heart, Lung, and Blood Institute (NHLBI) has awarded a Project Grant under the Cardiovascular Diseases Research program (CFDA 93.837) to The Trustees of Columbia University in the City of New York. The $688,291 grant will fund the development and clinical validation of a novel 3D ultrasound technique called Electromechanical Wave Imaging (EWI) for non-invasive, personalized cardiac arrhythmia mapping. Over a 5-year period ending in June 2029, the project aims to demonstrate that...
The National Heart, Lung, and Blood Institute (NHLBI), under the Cardiovascular Diseases Research program (CFDA 93.837), awarded a $1,013,000 Project Grant to Endolynx Inc. to develop an Optical Sensor-Enabled Endotracheal Tube (OS-ETT). The goal of this SBIR Phase I project is to demonstrate the feasibility of the OS-ETT, which aims to reduce the risk and incidence of esophageal intubation and unintended extubation during the over 30 million intubations performed annually in the U.S. The OS-ETT...
The National Heart, Lung, and Blood Institute (NHLBI) awarded a $269,922 Project Grant under the Cardiovascular Diseases Research program (CFDA 93.837) to Steth X Microsystems Inc. to develop a smart, wearable contact microphone patch for extended and remote monitoring of lung functions. The goal is to create a low-profile, battery-powered wireless device capable of accurately detecting and quantifying adventitious lung sounds as well as breathing abnormalities in patients with respiratory...
This Project Grant award from the National Heart Lung and Blood Institute (NHLBI) under the Cardiovascular Diseases Research program (CFDA 93.837) aims to develop a modern Electrical Impedance Tomography (EIT) device for monitoring children in the Intensive Care Unit (ICU). The $299,900 award to Goodlife Inventors LLC will fund efforts to (1) generate initial designs for an advanced lightweight EIT belt and (2) assess the technical feasibility of a miniaturized, easier to use EIT core device. If...
This Project Grant award of $1,331,984.00 from the National Heart, Lung, and Blood Institute (CFDA 93.837 - Cardiovascular Diseases Research) supports research to develop new lung quantitative ultrasound (LQUS) metrics for monitoring pulmonary edema due to heart failure and idiopathic pulmonary fibrosis. The primary awardee, North Carolina State University, will work to mitigate chest-wall effects, optimize data acquisition, and apply LQUS methods in human patients with heart failure and...
This Project Grant award from the National Heart, Lung, and Blood Institute (NHLBI) under CFDA 93.837 - Cardiovascular Diseases Research aims to develop an integrated super-resolution cardiac magnetic resonance imaging and deep learning (CMR-DL) technology to isolate and quantify the contributions of passive and active remodeling events to left ventricular diastolic dysfunction (LVDD). The total award amount is $702,534, with a project period from March 6, 2025 to December 31, 2029. The awardee,...
The National Heart, Lung, and Blood Institute (NHLBI) awarded a $706,806 Project Grant under CFDA 93.837 (Cardiovascular Diseases Research) to Elimu Informatics Inc., a small business software company in California. The grant funds the design, development, and evaluation of TIBSA (Tailored Interoperable Guideline-Based Clinical Decision-Support System for Asthma), a clinical decision support application that incorporates the 2020 NHLBI asthma management guidelines, patient-specific data,...
The National Heart, Lung, and Blood Institute (NHLBI), under the Cardiovascular Diseases Research program (CFDA 93.837), awarded a $400,000 Project Grant to Electronic Biosciences, Inc. on Sep 20, 2024. The grant supports the development of an innovative analytical testing device to quantitatively characterize lipoprotein particles in blood. This technology will enable rapid, precise, and cost-effective measurement of lipoprotein size, concentration, and other physical properties, which are...
The National Heart, Lung, and Blood Institute (NHLBI) awarded a $306,530 Project Grant under the Cardiovascular Diseases Research program (CFDA 93.837) to Spinhance LLC, a for-profit limited liability company located in Rydal, Pennsylvania. The grant aims to design, build, and evaluate a novel cardiopulmonary imaging device for continuous administration of the magnetic resonance imaging (MRI) contrast agent hyperpolarized xenon-129. This system is intended to support a new paradigm for...
This National Heart, Lung, and Blood Institute (NHLBI) funded Project Grant under the Cardiovascular Diseases Research program (CFDA 93.837) seeks to develop a novel 3D dynamic MRI (3D-DMRI) scheme to quantify airway collapse in patients with obstructive sleep apnea (OSA). The $426,717 award from August 2024 to May 2029 will be used by The University of Iowa to systematically validate the 3D-DMRI approach and assess its clinical utility for characterizing patterns of airway collapse, both in the...